Key result
Recombinant streptokinase matches natural streptokinase for post-thrombolysis coronary patency.
Why the study?
The comparative effects on hemostasis and coronary patency of recombinant versus natural streptokinases in AMI patients were not established.
Does recombinant streptokinase provide similar coronary patency and hemostasis effects compared to natural streptokinase in patients with acute myocardial infarction?
RCT (n=224)
Blinded endpoint evaluation
Randomized
Yes
Does recombinant streptokinase provide similar coronary patency and hemostasis effects compared to natural streptokinase in patients with acute myocardial infarction?
Absolute Event Rate: 67.1% vs 70.7%
p-value: p=non-significant difference
Recombinant streptokinase demonstrates comparable efficacy to natural streptokinase regarding coronary patency and hemostatic changes in patients with acute myocardial infarction.
Recombinant streptokinase offers a viable alternative to natural streptokinase in AMI thrombolysis; confirms similar coronary patency in this RCT.
AIM: To compare the effects on hemostasis and coronary patency of recombinant (rSK) and natural (nSK) streptokinases in patients with acute myocardial infarct (AMI). METHODS: Patients from 7 hospitals, <70 years old, less than 12 h after the onset of AMI symptoms, with ST segment elevation or bundle branch block, without contraindications for thrombolytic therapy, were randomized to receive 1.5 million units of nSK or rSK in a one-hour intravenous infusion. Fibrinogen, fibrinogen degradation products (FDP) and thrombin time were monitored. A coronary angiography was performed after 5-10 days in those patients who gave their consent and did not refer allergy to iodine contrasts. Images were blindly evaluated by an independent committee. RESULTS: 224 patients were randomized (113 nSK and 111 rSK). Groups were equivalent in all baseline and demographic variables except that rSK patients were 5.4 years significantly older. They were also comparable in all the clinical characteristics. Both treatments produced the same changes in hemostasis. Fibrinogen levels decreased, FDP and thrombin time increased immediately after thrombolysis and returned to baseline 2 days afterwards, but fibrinogen values continued to increase up to day 10. Coronary patency (TIMI 2-3) rates at 7.8+/-2.7 and 8.0+/-2.7 days after fibrinolysis were 70.7% and 67.1% for nSK and rSK groups, respectively (non-significant difference). Hypotension and arrhythmias were the most frequent adverse events in both groups, which did not differ in this respect either. Five patients from each group died, one of them (nSK) due to gastroduodenal bleeding probably related to treatment. CONCLUSIONS: rSK behaved similarly to nSK regarding coronary patency at 8 days after thrombolysis and the changes induced on fibrinogen, FDP and thrombin time. These results suggest that the same benefit/risk profile reported for AMI patients treated with nSK can be expected for rSK.
No takes yet. Share an insight, caveat, or question.
A 1999 study conducted an RCT in Acute myocardial infarct (AMI) (n=224). Recombinant streptokinase (rSK) vs. Natural streptokinase (nSK) was evaluated on Coronary patency (TIMI 2-3) at 5-10 days (p=non-significant difference). Recombinant streptokinase resulted in similar coronary patency rates compared to natural streptokinase at 8 days after thrombolysis (67.1% vs 70.7%, non-significant difference).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: